Brief: ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2024 Results
04/03/2025 21:56
March 4 (Reuters) - Chromadex Corp CDXC.O: CHROMADEX CORPORATION Q4 SALES USD 29.125 MILLION CHROMADEX CORPORATION Q4 OPERATING EXPENSES USD 11.086 MILLION CHROMADEX CORPORATION Q4 NET INCOME USD 7.179 MILLION CHROMADEX CORPORATION Q4 OPERATING INCOME USD 7.111 MILLION CHROMADEX CORPORATION Q4 GROSS PROFIT USD 18.197 MILLION CHROMADEX CORP: QTRLY EARNINGS PER SHARE $0.09 CHROMADEX CORP - PROJECTS 18% YOY REVENUE GROWTH FOR 2025 Source text: ID:nBw70Qvvha Further company coverage: CDXC.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Niagen Bioscience
See all newsAs weight-loss drug users turn to dietary supplements, doctors, regulators raise flags
Niagen Bioscience Inc reports results for the quarter ended June 30 - Earnings Summary
Niagen Bioscience Q2 net sales fall, missing estimates
Niagen Bioscience Inc expected to post earnings of 2 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-SpaceX, Sandisk, Salesforce